Evidence map›Paper›PMID 38854908›Full record

ArticleJournal of the Endocrine Society2024

Interference With VIP to Distinguish Between Real and False VIPoma: National Study From the French Endocrine Tumors Group.

Benjamin Chevalier, Delphine Bonnet, Come Lepage, Marine Perrier, Françoise Borson-Chazot, Juliette Abeillon, Jean Bernard Delobel, Arnaud Jannin, Julien Hadoux, Magalie Haissaguere and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Benjamin ChevalierDepartment of Nuclear Medicine, Lille University Hospital, Lille 59000, France.ORCID https://orcid.org/0000-0001-6449-3148
Delphine BonnetDepartment of Internal Medicine and Digestive Diseases, CHU Toulouse, Toulouse 31059, France.ORCID https://orcid.org/0000-0002-8108-0852
Come LepageGastroenterology and Digestive Oncology, Hôpital Universitaire Le Bocage, Dijon 21079, France.ORCID https://orcid.org/0000-0001-9211-4707
Marine PerrierUniversité Reims Champagne-Ardenne, Department of Gastroenterology and Digestive Oncology, Reims University Hospital, 51092 Reims, France.ORCID https://orcid.org/0000-0002-4528-5471
Françoise Borson-ChazotHospices Civils de Lyon, Hôpital Louis Pradel, Fédération d'Endocrinologie, Lyon 69500, France.ORCID https://orcid.org/0000-0003-2515-7840
Juliette AbeillonHospices Civils de Lyon, Hôpital Louis Pradel, Fédération d'Endocrinologie, Lyon 69500, France.ORCID https://orcid.org/0000-0003-2303-6762
Jean Bernard DelobelHôpital Yves le Foll, Service de Gastroentérologie, Saint Brieuc 22000, France.
Arnaud JanninSchool of Medicine, University of Lille, Lille 59000, France.ORCID https://orcid.org/0000-0002-6031-4816
Julien HadouxDepartment of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Cancer Center, Villejuif 94800, France.ORCID https://orcid.org/0000-0002-1276-3289
Magalie HaissaguereEndocrinology and Endocrine Oncology Department, Haut Leveque Hospital, University Hospital of Bordeaux, Bordeaux 33600, France.ORCID https://orcid.org/0000-0001-5007-7602
Catherine Lombard-BohasHospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Oncologie, Lyon 69003, France.ORCID https://orcid.org/0000-0003-3896-4588
Thomas WalterHospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Oncologie, Lyon 69003, France.ORCID https://orcid.org/0000-0002-4199-4561
Laurence ChardonService de Biochimie, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron 69500, France.ORCID https://orcid.org/0000-0002-3462-4239

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Vasoactive intestinal peptide (VIP)-secreting tumors (VIPomas) are digestive neuroendocrine tumors in which the hormonal secretion is life-threatening. Biological confirmation is obtained by demonstrating an elevation in plasma VIP, usually using radioimmunoassay (RIA). In some cases, analytical interference is suspected. We developed 3 different techniques to detect interference in VIP RIA. Methods: Three techniques were used: RIA after Sephadex column chromatography separation, RIA after polyethylene glycol precipitation, and Results: A total of 15 patients with FPV elevation and 9 RV patients were included. Interference was detected in all FPV patients vs none in RV. Clinical and biochemical parameters did not differ between FPV and RV patients, but VIP concentration in RIA was significantly higher in FPV patients than in RV patients (228 pmol/L vs 66 pmol/L, Conclusion: We developed 3 different laboratory techniques to reveal interference in RIA VIP assays. The diagnostic performance of all 3 was excellent. These techniques must be employed in cases of discordance between VIP elevation and clinical presentation.

Indexed as

analytic interferenceneuroendocrine tumorvasoactive intestinal peptide

Identifiers

PMID38854908
PMCPMC11156571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.